XellSmart has initiated a multicenter Phase II registrational clinical trial for XS411, an allogeneic, off-the-shelf iPSC-derived dopaminergic neural progenitor cell therapy targeting primary Parkinson’s disease. The trial, led by Beijing Tiantan Hospital and involving collaborators such as Peking Union Medical College Hospital and the Second Affiliated Hospital of Soochow University, aims to enroll 30 patients aged 50 to 75 with a disease duration of 5 to 15 years. Participants will be randomized in a 2:1 ratio to receive either XS411 or standard anti-Parkinsonian pharmacotherapy, with a primary follow-up period of 12 months and extended follow-up for the experimental group up to 24 months.

The significance of this trial lies in the promising results from Phase I, which demonstrated significant improvements in core motor outcomes, longer favorable ON time, enhanced daily quality of life, and increased 18F-DOPA PET-CT uptake in the putamen, indicative of graft survival and function. Importantly, no adverse events were attributed to the transplanted cells, suggesting a favorable safety profile. With clearances from both China’s NMPA and the US FDA obtained in 2025, this Phase II trial is positioned to provide robust evidence of efficacy and safety, paving the way for a future Phase III study.

The implications of this trial extend to the broader field of regenerative medicine and neurodegenerative disease treatment paradigms. If successful, XS411 could shift the current landscape of Parkinson’s disease management, potentially offering a novel therapeutic option that addresses the underlying pathology rather than merely alleviating symptoms. This advancement may accelerate the development timelines for similar cell-based therapies and encourage more investment in iPSC-derived treatments for neurodegenerative conditions.

Source: longevity.technology